## CITATION REPORT List of articles citing

Tolerability and Pharmacokinetics of Hydronidone, an Antifibrotic Agent for Hepatic Fibrosis, after Single and Multiple Doses in Healthy Subjects: an Open-Label, Randomized, Dose-Escalating, First-in-Human Study

DOI: 10.1007/s13318-015-0316-z European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 37-48.

Source: https://exaly.com/paper-pdf/65825625/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Metabolic characterization of the early stage of hepatic fibrosis in rat using GC-TOF/MS and multivariate data analyses. <i>Biomedical Chromatography</i> , <b>2017</b> , 31, e3899	1.7	8
8	Anti-Fibrotic Therapies from Other Organs: What the Gut Can Learn from the Liver, Skin, Lung and Heart. <b>2018</b> , 347-385		
7	Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 730176	5.7	13
6	Antihepatic Fibrosis Drugs in Clinical Trials. Journal of Clinical and Translational Hepatology, <b>2020</b> , 8, 304	4-3.12	7
5	Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis <i>Drug Discovery Today</i> , <b>2021</b> ,	8.8	2
4	Targeting fibrosis: mechanisms and clinical trials. Signal Transduction and Targeted Therapy, 2022, 7,	21	5
3	Hydronidone for the treatment of liver fibrosis related to chronic hepatitis B: a Phase 2 randomized controlled trial. <i>Clinical Gastroenterology and Hepatology</i> , <b>2022</b> ,	6.9	
2	A novel, simple and reliable method for the determination of hydronidone and its metabolites M3 and M4 in human plasma and urine by HPLC-MS/MS and its application to a pharmacokinetic study in health Chinese subjects. <b>2022</b> , 655, 114842		0
1	A Pharmacokinetic Drug <b>D</b> rug Interactions Study between Entecavir and Hydronidone, a Potential Novel Antifibrotic Small Molecule, in Healthy Male Volunteers.		O